Sun JM - Search Results

1

Six versus fewer planned cycles of first-line platinum-based chemotherapy for non-small-cell lung cancer: a systematic review and meta-analysis of individual patient data.

Rossi A, Chiodini P, Sun JM, O'Brien ME, von Plessen C, Barata F, Park K, Popat S, Bergman B, Parente B, Gallo C, Gridelli C, Perrone F, Di Maio M. Rossi A, et al. Among authors: sun jm. Lancet Oncol. 2014 Oct;15(11):1254-62. doi: 10.1016/S1470-2045(14)70402-4. Epub 2014 Sep 14. Lancet Oncol. 2014. PMID: 25232001 Review.

2

Efficacy and toxicity of pemetrexed as a third-line treatment for non-small cell lung cancer.

Sun JM, Lee KW, Kim JH, Kim YJ, Yoon HI, Lee JH, Lee CT, Lee JS. Sun JM, et al. Jpn J Clin Oncol. 2009 Jan;39(1):27-32. doi: 10.1093/jjco/hyn118. Epub 2008 Oct 24. Jpn J Clin Oncol. 2009. PMID: 18952704

3

The relationship between response to previous systemic treatment and the efficacy of subsequent pemetrexed therapy in advanced non-small cell lung cancer.

Sun JM, Oh DY, Lee SH, Kim DW, Im SA, Kim TY, Lee JS, Kim YW, Heo DS, Bang YJ. Sun JM, et al. Lung Cancer. 2010 Jun;68(3):427-32. doi: 10.1016/j.lungcan.2009.07.013. Epub 2009 Aug 11. Lung Cancer. 2010. PMID: 19674811

4

Accuracy of RECIST 1.1 for non-small cell lung cancer treated with EGFR tyrosine kinase inhibitors.

Sun JM, Ahn MJ, Park MJ, Yi JH, Kim TS, Chung MJ, Park YH, Ahn JS, Park K. Sun JM, et al. Lung Cancer. 2010 Jul;69(1):105-9. doi: 10.1016/j.lungcan.2009.09.014. Epub 2009 Dec 2. Lung Cancer. 2010. PMID: 19959251

5

Unsuspected pulmonary emboli in lung cancer patients: the impact on survival and the significance of anticoagulation therapy.

Sun JM, Kim TS, Lee J, Park YH, Ahn JS, Kim H, Kwon OJ, Lee KS, Park K, Ahn MJ. Sun JM, et al. Lung Cancer. 2010 Sep;69(3):330-6. doi: 10.1016/j.lungcan.2009.11.015. Epub 2009 Dec 14. Lung Cancer. 2010. PMID: 20007002

6

Who are less likely to receive subsequent chemotherapy beyond first-line therapy for advanced non-small cell lung cancer? Implications for selection of patients for maintenance therapy.

Sun JM, Park JO, Won YW, Kim JH, Yun J, Lee J, Park YH, Ahn JS, Ahn MJ, Park K. Sun JM, et al. J Thorac Oncol. 2010 Apr;5(4):540-5. doi: 10.1097/JTO.0b013e3181d3504d. J Thorac Oncol. 2010. PMID: 20195170 Free article.

7

The different efficacy of gefitinib or erlotinib according to epidermal growth factor receptor exon 19 and exon 21 mutations in Korean non-small cell lung cancer patients.

Sun JM, Won YW, Kim ST, Kim JH, Choi YL, Lee J, Park YH, Ahn JS, Park K, Ahn MJ. Sun JM, et al. J Cancer Res Clin Oncol. 2011 Apr;137(4):687-94. doi: 10.1007/s00432-010-0928-2. Epub 2010 Jun 16. J Cancer Res Clin Oncol. 2011. PMID: 20552223

8

Comparison of gefitinib versus erlotinib in patients with nonsmall cell lung cancer who failed previous chemotherapy.

Kim ST, Lee J, Kim JH, Won YW, Sun JM, Yun J, Park YH, Ahn JS, Park K, Ahn MJ. Kim ST, et al. Among authors: sun jm. Cancer. 2010 Jun 15;116(12):3025-33. doi: 10.1002/cncr.25130. Cancer. 2010. PMID: 20564408 Free article.

9

Predictors of skeletal-related events in non-small cell lung cancer patients with bone metastases.

Sun JM, Ahn JS, Lee S, Kim JA, Lee J, Park YH, Park HC, Ahn MJ, Ahn YC, Park K. Sun JM, et al. Lung Cancer. 2011 Jan;71(1):89-93. doi: 10.1016/j.lungcan.2010.04.003. Epub 2010 Jul 3. Lung Cancer. 2011. PMID: 20598769

10

Prognostic model to predict outcomes in non-small cell lung cancer patients with erlotinib as salvage treatment.

Kim ST, Lee J, Sun JM, Park YH, Ahn JS, Park K, Ahn MJ. Kim ST, et al. Among authors: sun jm. Oncology. 2010;79(1-2):78-84. doi: 10.1159/000320190. Epub 2010 Nov 12. Oncology. 2010. PMID: 21071994

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

665 results

Search Page

Filters